Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | WEE1 | P30291 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | TPH1 | P17752 | 5/20 | 0.38 |
| ▸ | CIT | O14578 | 2/20 | 0.37 |
| ▸ | GRB2 | P62993 | 1/20 | 0.37 |
| ▸ | PRKCA | P17252 | 1/20 | 0.37 |
| ▸ | PRKCH | P24723 | 1/20 | 0.37 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7105541 | 1.00 | SLC7A5 (0.42) | SLC7A5HSD17B10WEE1PTGS1ALPI | |
| SCHEMBL6537407 | 0.92 | SLC7A5 (0.43) | SLC7A5HSD17B10WEE1PTGS1ALPI | |
| SCHEMBL2990667 | 0.92 | SLC7A5 (0.43) | SLC7A5HSD17B10WEE1PTGS1ALPI | |
| SCHEMBL5262133 | 0.88 | CIT (0.39) | CITTRPV1HDAC3HDAC1HDAC6 | |
| SCHEMBL5262134 | 0.88 | CIT (0.39) | CITTRPV1HDAC3HDAC1HDAC6 | |
| SCHEMBL5149495 | 0.86 | EGFR (0.40) | HSD17B10CITTRPV1HDAC3HDAC1 | |
| SCHEMBL7100085 | 0.86 | SLC7A5 (0.49) | SLC7A5HSD17B10WEE1PTGS1ALPI | |
| SCHEMBL5149509 | 0.83 | TRPV1 (0.39) | TRPV1HDAC3HDAC1HDAC6KDM4E | |
| SCHEMBL5260061 | 0.80 | HDAC3 (0.40) | CITHDAC3HDAC1HDAC6EGFR | |
| SCHEMBL5260057 | 0.80 | HDAC3 (0.40) | CITHDAC3HDAC1HDAC6EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786177-B2 | Phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2010-08-31 | — | — | US | disclosed |
| US-7645770-B2 | Phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2010-01-12 | — | — | US | disclosed |
| US-20090186914-A1 | Phenylalanine Enamide Derivatives | UCB PHARMA, S.A. (BE) | 2009-07-23 | — | — | US | disclosed |
| US-7531549-B2 | Phenylalanine enamide derivatives | UCB PHARMA, S.A. (BE) | 2009-05-12 | — | — | US | disclosed |
| US-20090105291-A1 | Phenylalanine Enamide Derivatives | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-7501437-B2 | Phenylalanine enamide derivatives | UCB PHARMA, S.A. (BE) | 2009-03-10 | — | — | US | disclosed |
| EP-1622867-B1 | N-(2-PHENYLETHYL)SULFAMIDE DERIVATIVES AS INTEGRIN ALPHA4 ANTAGONISTS | ALMIRALL LAB (ES) | 2007-09-19 | — | — | EP | disclosed |
| US-20070179183-A1 | N-(2-phenylethyl)sulfamide derivatives as integrin alpha4 antagonists | ALMIRALL, S.A. (ES) | 2007-08-02 | — | — | US | disclosed |
| EP-1370531-B1 | PHENYLALANINE ENAMIDE DERIVATIVES POSSESSING A CYCLOBUTENE GROUP, FOR USE AS INTEGRIN INHIBITORS | CELLTECH R&D LTD (GB) | 2007-02-28 | — | — | EP | disclosed |
| US-20070027174-A1 | Phenylalanine Enamide Derivatives | CELLTECH R&D LIMITED | 2007-02-01 | — | — | US | disclosed |
| US-7122556-B2 | Phenylalanine enamide derivatives | CELLTECH R&D LIMITED (GB) | 2006-10-17 | — | — | US | disclosed |
| EP-1622867-A1 | N-(2-PHENYLETHYL)SULFAMIDE DERIVATIVES AS INTEGRIN ALPHA4 ANTAGONISTS | Almirall Prodesfarma, S.A. (ES) | 2006-02-08 | — | — | EP | disclosed |
| US-6878718-B2 | Phenylalanine enamide derivatives | CELLTECH R&D LIMITED (GB) | 2005-04-12 | — | — | US | disclosed |
| US-20050038084-A1 | Phenylalanine enamide derivatives | CELLTECH R&D LIMITED | 2005-02-17 | — | — | US | disclosed |
| WO-2004099126-A1 | N-(2-PHENYLETHYL)SULFAMIDE DERIVATIVES AS INTEGRIN α4 ANTAGONISTS | ALMIRALL PRODESFARMA SA (ES) | 2004-11-18 | — | — | WO | disclosed |
| US-20030162799-A1 | Carbocyclic oxo, carboxy amines such as 3-(4-(3,5-Dichloro-4-pyridylcarboxamido)phenyl)-2-(2-propylamino-3,4 -dioxocyclobut-1-enyl)amino)propanoic acid, used as integrin antagonists; antiinflammatory agents | CELLTECH R&D LIMITED (GB) | 2003-08-28 | — | — | US | disclosed |
| US-6518283-B1 | To modify integrin function in such a way as to beneficially modulate cell adhesion | CELLTECH R&D LIMITED (GB) | 2003-02-11 | — | — | US | disclosed |
| US-20020169336-A1 | Phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027174-A1 | Phenylalanine Enamide Derivatives | PAH, HRH3, AGTR2 | SLC7A5 942/4885HSD17B10 2359/4885WEE1 2362/4885 |
| US-20090105291-A1 | Phenylalanine Enamide Derivatives | PAH, HRH3, PRLHR | SLC7A5 1081/4885HSD17B10 2789/4885WEE1 1841/4885 |
| US-20070179183-A1 | N-(2-phenylethyl)sulfamide derivatives as integrin alpha4 antagonists | ITGA4, ITGB4, ITGA2 | SLC7A5 2036/4885HSD17B10 4542/4885WEE1 3593/4885 |
| US-20050038084-A1 | Phenylalanine enamide derivatives | PAH, ARRB1, ACVR2B | SLC7A5 1024/4885HSD17B10 2509/4885WEE1 2344/4885 |
| US-20020169336-A1 | Phenylalanine enamide derivatives | CCR1, AHR, PAH | SLC7A5 1667/4885HSD17B10 1822/4885WEE1 2536/4885 |
| US-20090186914-A1 | Phenylalanine Enamide Derivatives | PAH, HRH3, PRLHR | SLC7A5 1081/4885HSD17B10 2789/4885WEE1 1841/4885 |
| US-20030162799-A1 | Carbocyclic oxo, carboxy amines such as 3-(4-(3,5-Dichloro-4-pyridylcarboxamido)phenyl)-2-(2-propylamino-3,4 -dioxocyclobut-1-enyl)amino)propanoic acid, used as integrin antagonists; antiinflammatory agents | ICAM1, VCAM1, CCR1 | SLC7A5 778/4885HSD17B10 3264/4885WEE1 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.